Printer Friendly

CONNAUGHT LABORATORIES RECEIVES CDC CONTRACT TO SUPPLY ACELLULAR DTP VACCINE FOR PUBLIC SECTOR

 CONNAUGHT LABORATORIES RECEIVES CDC CONTRACT
 TO SUPPLY ACELLULAR DTP VACCINE FOR PUBLIC SECTOR
 SWIFTWATER, Pa., Nov. 4 /PRNewswire/ -- Connaught Laboratories, Inc. announced today that it has been awarded a one-year contract by the U.S. Centers for Disease Control (CDC) to supply the Federal government with an acellular pertussis vaccine that protects children as young as 15 months of age against diphtheria, tetanus and pertussis (DTP). This is the first such vaccine purchased under Federal government contract.
 The Connaught vaccine,. Tripedia (TM), Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, was approved for marketing by the Food and Drug Administration in August of this year. The pertussis component of the vaccine induces immunity against whooping cough. Tripedia is produced using purified, inactivated components of the pertussis bacterial organism instead of inactivated whole bacterial cells. Indicated for use as the fourth and/or fifth doses in the five- dose DTP vaccination series, Tripedia is as protective as whole-cell pertussis vaccine, which is also produced by Connaught Laboratories, Inc. The first three doses, recommended at two, four and six months of age, require whole-cell pertussis DTP vaccine.
 Under the terms of the one-year contract, Connaught Laboratories, Inc. will provide all of the acellular pertussis DTP vaccine that the Federal government supplies to state and territorial health departments for use in public immunization programs. The contract was awarded on the basis of a competitive bid. Connaught Laboratories, Inc. also holds the current CDC contract to provide whole-cell pertussis DTP vaccine.
 Connaught Laboratories, Inc., which is headquartered in Swiftwater, is a wholly owned subsidiary of Connaught Laboratories, Ltd., part of the Pasteur Merieux group of companies, the world's largest developer of vaccines for human use. Connaught Laboratories, Inc. provides the broadest range of vaccines and biologicals commercially available in the United States from a single company.
 The company is actively involved in immunological research as well as the manufacture, marketing and distribution of vaccines against diphtheria, tetanus, pertussis, Haemophilus influenzae type B, influenza, yellow fever, rabies and other diseases.
 -0- 11/4/92
 /NOTE TO EDITORS: The package insert is available from Sherri Michelstein at 212-557-7111
 /CONTACT: Lenore Cooney or Sherri Michelstein of Cooney/Waters Group, 212-557-7111, for Connaught Laboratories, Inc./ CO: Connaught Laboratories, Inc. ST: Pennsylvania IN: MTC SU: CON


AH-TS -- NY058 -- 2592 11/04/92 14:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1992
Words:387
Previous Article:HALIFAX RELEASES SECOND-QUARTER AND FIRST-HALF RESULTS
Next Article:ADAGE, INC. TERMINATES PRESIDENT AND SIX OTHER EXECUTIVES AT ITS ALLISTER ACCESS CONTROLS SUBSIDIARY.
Topics:


Related Articles
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
NEW VACCINES ADDED TO CHILDHOOD IMMUNIZATION ARSENAL
SMITHKLINE BEECHAM ANNOUNCES PEDIATRIC VACCINE AGREEMENT WITH MEDEVA
PASTEUR MERIEUX-CONNAUGHT SIGNS A RESEARCH AGREEMENT WITH THE AGENCE NATIONALE DE RECHERCHES SUR LE SIDA
CONNAUGHT LABORATORIES, INC. COMMENTS ON NIAID PERTUSSIS TRIALS
FDA LICENSES TRIPEDIA AS FIRST ACELLULAR PERTUSSIS VACCINE FOR INFANT USE
FDA Licenses Tripedia as First Acellular Pertussis Vaccine for Infant Use
Background on Tripedia(R)
U.S. Food And Drug Administration Licenses INFANRIX(TM) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed)
Pasteur Merieux Connaught and Cistron Biotechnology Enter Into a Letter of Intent for an Equity Investment and an Interleukin-1b Vaccine Adjuvant...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters